The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study
Abstract
Objective To investigate the association between type 2 diabetes mellitus (T2DM) and subsequent Parkinson disease (PD). Methods Linked English national Hospital Episode Statistics and mortality data (1999–2011) were used to conduct a retrospective cohort study. A cohort of individuals admitted for hospital care with a coded diagnosis of T2DM was constructed, and compared to a reference cohort. Subsequent PD risk was estimated using Cox regression models. Individuals with a coded diagnosis of cerebrovascular disease, vascular parkinsonism, drug-induced parkinsonism, and normal pressure hydrocephalus were excluded from the analysis. Results A total of 2,017,115 individuals entered the T2DM cohort and 6,173,208 entered the reference cohort. There were significantly elevated rates of PD following T2DM (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.29–1.35; p < 0.001). The relative increase was greater in those with complicated T2DM (HR 1.49, 95% CI 1.42–1.56) and when comparing younger individuals (HR 3.81, 95% CI 2.84–5.11 in age group 25–44 years). Conclusions We report an increased rate of subsequent PD following T2DM in this large cohort study. These findings may reflect shared genetic predisposition and/or disrupted shared pathogenic pathways with potential clinical and therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diabetes is a well-established risk factor for PD, and has been linked to a faster disease progression”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [613]
Citations
Cites
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 2×
“A recent doubleblind trial involving 62 patients with PD randomly assigned to placebo or exenatide 2-mg weekly injections showed positive and persistent effects on motor symptoms measured by section 3 of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale.(9)Whether the effect is secondary to sympto…”
BackgroundSelf-citationMeta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. E. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 834
Self-citationType 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Diabetes and Risk of Parkinson’s Disease
Xu, Q., Park, Y., Huang, X., Hollenbeck, A. R., Blair, A. E., Schatzkin, A. G., & Chen, H. (2011) · Diabetes Care · doi:10.2337/dc10-1922 · Cited by 282
Diabetes and Risk of Parkinson’s Disease
Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., & Pezzoli, G. (2011) · Diabetes Care · doi:10.2337/dc11-1584 · Cited by 247
Obesity, diabetes, and risk of Parkinson's disease
Palacios, N., Gao, X., McCullough, M. L., Jacobs, E. J., Patel, A. V., Mayo, T. L., Schwarzschild, M. A., & Ascherio, A. (2011) · Movement Disorders · doi:10.1002/mds.23855 · Cited by 170
Neuroendocrine abnormalities in Parkinson's disease
Pablo‐Fernández, E. D., Breen, D. P., Bouloux, P. M., Barker, R. A., Foltynie, T., & Warner, T. T. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314601 · Cited by 89
Self-citationSantiago, J. A., & Potashkin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083940 · Cited by 79
Association between Parkinson's disease and diabetes: Data from NEDICES study
Pablo‐Fernández, E. D., Hidalgo, F. S., Benito‐León, J., & Bermejo‐Pareja, F. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12793 · Cited by 63
Research works printed but not linked: 1
- National Institute for Health and Care Excellence. Parkinson's Disease in Adults. NICE Guideline NG71 [online]. Available at: nice.org.uk/guidance/NG71. Accessed August 1, 2017.
Cited by
Sorted by citations
Items 101–200 of 242
Faizan, M., Sarkar, A., & Singh, M. P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101727 · Cited by 22
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
Jones-Tabah, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167927 · Cited by 18
Zhong, Q., & Wang, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1109914 · Cited by 19
Chen, L., Tao, Y., Li, J., & Kang, M. (2022) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2022.10.023 · Cited by 18
Bantounou, M. A., Shoaib, K., Mazzoleni, A., Modalavalasa, H., Kumar, N. S., & Philip, S. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100158 · Cited by 18
Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study
Rozani, V., Bezimianski, M. G., Azuri, J., Bitan, M., & Peretz, C. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107132 · Cited by 18
Gialluisi, A., Bartolo, M. I. D., Costanzo, S., Belvisi, D., Falciglia, S., Ricci, M., Castelnuovo, A. F. D., Panzera, T., Donati, M. B., Fabbrini, G., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11803-1 · Cited by 17
Interaction of Proteins Involved in Neuronal Proteinopathies
Kulichikhin, K. Y., Malikova, O. A., Zobnina, A. E., Zalutskaya, N. M., & Rubel, A. A. (2023) · Life · doi:10.3390/life13101954 · Cited by 17
Molsberry, S. A., Bjørnevik, K., Hughes, K. C., Zhang, Z. J., Jeanfavre, S., Clish, C. B., Healy, B. C., Schwarzschild, M. A., & Ascherio, A. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191896 · Cited by 17
Targeting hIAPP fibrillation: A new paradigm to prevent β-cell death?
Guillemain, G., Lacapère, J.-J., & Khemtémourian, L. (2022) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2022.184002 · Cited by 18
Parkinson Disease and the Gut: A Primer for Gastroenterologists
Sharma, A., Voigt, R. M., Goetz, C. G., & Keshavarzian, A. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003508 · Cited by 17
Epidemiological Evidence for an Immune Component of Parkinson’s Disease
González-Latapí, P., & Marras, C. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223180 · Cited by 17
Park, K. W., Hwang, Y. S., Lee, S. H., Jo, S., & Chung, S. J. (2023) · Journal of Movement Disorders · doi:10.14802/jmd.22175 · Cited by 16
Parkinson’s disease is associated with clonal hematopoiesis with TET2 mutation
Woo, K. A., Kim, H., Lee, C. Y., Shin, J. H., Sun, C.-H., Im, H., An, H., Lim, J., Choi, S., Koh, Y., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00784-1 · Cited by 16
Kang, Y., Feng, Z., Zhang, Q., Liu, M., Li, Y., Yang, H., Zheng, L., Cheng, C., Zhou, W., Lou, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14443 · Cited by 16
From Prodromal to Overt Parkinson’s Disease: Towards a New Definition in the Year 2040
Berg, D., & Postuma, R. B. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181457 · Cited by 16
Ntetsika, T., Catrina, S., & Markaki, I. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01910 · Cited by 16
Baldensperger, T., Preissler, M., & Becker, C. F. W. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00221k · Cited by 17
Vidal-Martínez, G., Yang, B. C., Vargas‐Medrano, J., & Perez, R. G. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00465 · Cited by 15
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 15
The comorbidity and co-medication profile of patients with progressive supranuclear palsy
Greten, S., Wegner, F., Jensen, I., Krey, L., Rogozinski, S., Fehring, M., Heine, J., Doll‐Lee, J., Pötter‐Nerger, M., Zeitzschel, M., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12006-4 · Cited by 14
Parkinson’s disease risk enhancers in microglia
Booms, A., Pierce, S. E., der Schans, E. J. C. V., & Coetzee, G. A. (2024) · iScience · doi:10.1016/j.isci.2024.108921 · Cited by 14
Žagare, A., Kurlovičs, J., Serra-Almeida, C., Ferrante, D., Frangenberg, D., Vitali, A., Gomez‐Giro, G., Jäger, C., Antony, P. M. A., Halder, R., et al. (2025) · Journal of Tissue Engineering · doi:10.1177/20417314241295928 · Cited by 19
Unveiling new secrets in Parkinson’s disease: The glycatome
Chegão, A., & Miranda, H. V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114309 · Cited by 15
Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder
Cardinali, D. P., & Garay, A. D. C. (2023) · Brain Sciences · doi:10.3390/brainsci13050797 · Cited by 14
Parkinson’s Disease and Diabetes Mellitus: Synergistic Effects on Pathophysiology and GI Motility
Yan, Y., Shimoga, D., & Sharma, A. (2023) · Current Gastroenterology Reports · doi:10.1007/s11894-023-00868-7 · Cited by 13
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 15
Zhang, X., Fan, Y., Luo, Y., Jin, L., & Li, S. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.46456 · Cited by 13
Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity
Huxford, B., Haque, T., Ben-Joseph, A., Simonet, C., Gallagher, D. A., Budu, C., Dobson, R., & Noyce, A. J. (2021) · Movement Disorders · doi:10.1002/mds.28829 · Cited by 13
Self-citationInsulin and disorders of behavioural flexibility
Sullivan, M., Fernández‐Aranda, F., Camacho‐Barcia, L., Harkin, A., Macrì, S., Mora‐Maltas, B., Jiménez‐Múrcia, S., O’Leary, A., Ottomana, A. M., Presta, M., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105169 · Cited by 15
The Role of a Ketogenic Diet in the Treatment of Dementia in Type 2 Diabetes Mellitus
Bai, L., Zhou, Y., Zhang, J., & Ma, J. (2023) · Nutrients · doi:10.3390/nu15081971 · Cited by 12
Bashir, B., Vishwas, S., Gupta, G., Paudel, K. R., Dureja, H., Kumar, P., Cho, H., Sugandhi, V. V., Kumbhar, P., Disouza, J., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102693 · Cited by 11
Bioinformatics analysis of copper death gene in diabetic immune infiltration
Lu, Z., Ding, L., Zhang, S., Jiang, X. Y., Wang, Q., Luo, Y., & Tian, X. (2023) · Medicine · doi:10.1097/md.0000000000035241 · Cited by 11
Abugroun, A., Taha, A., Abdel‐Rahman, M. E., Patel, P. J., Ali, I. A., & Klein, L. W. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.09.021 · Cited by 11
Li, Y., Vaughan, K. L., Wang, Y., Yu, S., Bae, E.-K., Tamargo, I. A., Kopp, K. O., Tweedie, D., Chiang, C., Schmidt, K. T., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01120-4 · Cited by 12
Abnormal functional connectivity of the frontostriatal circuits in type 2 diabetes mellitus
Fu, Y., Gu, M., Wang, R., Xu, J., Sun, S., Zhang, H., Huang, D., Zhang, Z., Peng, F., & Lin, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1055172 · Cited by 9
Nutt, J. G., & Bohnen, N. I. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181472 · Cited by 10
Kong, Y.-Y., Zhou, H.-C., Feng, H., Zhuang, J.-Y., Wen, T., Zhang, C.-C., Sun, B.-M., Wang, J., & Guan, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00682 · Cited by 9
Hormone replacement treatment in Turner syndrome.
Kanaka‐Gantenbein, C. (2006) · PubMed · Cited by 10
Zhao, Y., Wang, D., Wang, Y., Mu, D., Qu, L., & Li, R. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70487 · Cited by 10
Mauricio, D., Vlacho, B., Barrot, J., Mundet, X., Real, J., Kulisevsky, J., Ortega, E., Castelblanco, E., Julve, J., & Franch‐Nadal, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.800973 · Cited by 9
Insulin Sensitivity in De Novo Parkinson's Disease: A Hyperinsulinemic‐Euglycemic Clamp Study
Aziz, N. A., Roos, R. A. C., & Pijl, H. (2020) · Movement Disorders · doi:10.1002/mds.28181 · Cited by 9
Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease
Page, M. J., & Pretorius, E. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1733960 · Cited by 11
Tan, S., Chi, H., Pin, W., Zhao, R., Zhang, Q., Gao, Z., Xue, H., Tang, Q., & Li, G. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05436-4 · Cited by 12
Parkinson’s Disease Etiology: Insights and Associations with Phosphate Toxicity
Brown, R. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158060 · Cited by 8
Association of cardiovascular disease management drugs with Lewy body dementia: a case–control study
Scholz, S. W., Moroz, B. E., Sáez-Atiénzar, S., Chia, R., Cahoon, E. K., Dalgard, C. L., Dalgard, C. L., Adeleye, A., Soltis, A. R., Alba, C., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad346 · Cited by 8
Transplant and risk of Parkinson disease
Fan, J. H., Nielsen, S. S., Faust, I. M., & Racette, B. A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.013 · Cited by 8
Zhou, L., Ran, X.-R., Hong, F., Li, G., & Zhu, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00751 · Cited by 8
Navarro‐Otano, J., Llansó, L., Alejaldre, A., Porras, L. D., Santamaría, J., & Iranzo, Á. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12787-2 · Cited by 8
Goldacre, M. J., Benians, R. C., & Goldacre, R. (2021) · International Journal of Eating Disorders · doi:10.1002/eat.23596 · Cited by 7
Self-citationShepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Athauda, D. S., Evans, J. R., Mahoney‐Sanchez, L., Virdi, G. S., Lopez-Garcia, P., Wernick, A. I., Wagen, A. Z., D’Sa, K., Lachica, J., Strohbuecker, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582460 · Cited by 7
De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 6
Frailty and Parkinson’s disease: the role of diabetes mellitus
Komici, K., Pansini, A., Bencivenga, L., Rengo, G., Pagano, G., & Guerra, G. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1377975 · Cited by 6
Disease modifying therapies for Parkinson's disease: Novel targets
Vijiaratnam, N., & Foltynie, T. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108839 · Cited by 6
Jiang, D., Kong, Y., Ren, S., Cai, H., Zhang, Z., Huang, Z., Peng, F., Hua, F., Guan, Y., & Xie, F. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.02.011 · Cited by 6
Elgnainy, A. A., Hamed, M., Mohamed, W. O., & Sabri, N. (2021) · Neurology Research International · doi:10.1155/2021/2838669 · Cited by 3
Neilson, L. E., Quinn, J. F., & Lim, M. M. (2023) · Aging and Disease · doi:10.14336/ad.2022.1024 · Cited by 6
Cheng, Y., You, S., Wang, X., Ge, Y., Li, L., Ren, T., Chen, S., He, G., & Xue, S. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1620118 · Cited by 5
Atar, A., & Şahin, İ. N. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00743-7 · Cited by 5
Wang, Y., Gao, P.-P., Wu, Z., Jiang, B., Wang, Y., He, Z., Zhao, B., Tian, X., Gao, H., Cai, L., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119095 · Cited by 6
Mendel and urate: Acid test or random noise?
Brown, E. G., Goldman, S. M., & Tanner, C. M. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.08.005 · Cited by 5
Zolfaghari, S., Lewandowski, N., Pelletier, A., Naeimi, S. A., Gagnon, J., Brillon-Corbeil, M., Montplaisir, J. Y., & Postuma, R. B. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-212984 · Cited by 5
Zhou, Y., Jing, J., Zhang, Z., Pan, Y., Cai, X., Zhu, W., Li, Z., Liu, C., Liu, H., Meng, X., et al. (2024) · Human Brain Mapping · doi:10.1002/hbm.26598 · Cited by 4
Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease
De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 6
Plasmalogens in the Pathophysiology and Therapy of Age-Specific Diseases
Kytikovа, O. Y., Novgorodtseva, T. P., Antonyuk, M. V., & Gvozdenko, T. A. (2020) · Advances in Gerontology · doi:10.1134/s207905702003011x · Cited by 5
Zhang, Y., Zhou, L., Lian, H., Zhang, Y., Tong, S., & Wang, Z. (2021) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2021.102016 · Cited by 5
Dopamine-mediated autocrine inhibition of insulin secretion
Ferrero, E., Masini, M., Carli, M., Moscato, S., Beffy, P., Vaglini, F., Mattii, L., Corti, A., Scarselli, M., Novelli, M., et al. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112294 · Cited by 4
Qiu, X., Huang, Y., Cen, L., Chen, X., Lu, T., Shen, Y., Xu, P., Wang, J., & Xiao, Y. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135004 · Cited by 4
Aziz, N. A., & Wüllner, U. (2023) · Movement Disorders · doi:10.1002/mds.29341 · Cited by 4
Asah, C., Frandsen, R. A. V., Ibsen, R., Kjellberg, J., & Jennum, P. (2021) · Neuroepidemiology · doi:10.1159/000514175 · Cited by 4
Is Sudoscan a Reliable Tool in Detecting Small Fiber Neuropathy in Parkinson’s Disease patients?
Popescu, C. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0026 · Cited by 4
Zhang, R.-Y., Li, J.-Y., Liu, Y.-N., Zhang, Z.-X., Zhao, J., & Li, F.-J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1408053 · Cited by 3
Sarmadi, M., Rezaei, M., Poursadeghiyan, M., Soltaninejad, M., Moradi, S., Ahangarzadeh, M., Mahdiabadi, M. Z., & Rahimi, S. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08206-7 · Cited by 3
Gómez‐Mayordomo, V., Jiménez‐García, R., Zamorano‐León, J. J., Carabantes-Alarcón, D., Bodas-Pinedo, A., Hernández‐Barrera, V., López‐de‐Andrés, A., & Cuadrado‐Corrales, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134679 · Cited by 5
SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251359391 · Cited by 4
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Sharallah, O. A., Malakar, V. K., Salama, A. E., Elmaaz, S. M., Daba, S. A., & Poddar, N. K. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01702-0 · Cited by 3
Recent Developments in the Drug Treatment of Parkinson’s Disease
Leiter, S., Mahlknecht, P., & Poewe, W. H. (2026) · Drugs · doi:10.1007/s40265-026-02327-9 · Cited by 3
Xiang, M., Cao, S.-Y., Sun, X.-H., Hu, J.-W., Lv, M., Li, J., & Li, W. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00573-1 · Cited by 3
Obesity and the development of Parkinson’s disease within the Framingham Heart study cohort
O’Shea, S. A., Liu, Y., Liu, C., Frank, S., Shih, L. C., & Au, R. (2024) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2024.100291 · Cited by 3
Ribeiro, R., dos Santos, A. C. S., Calazans, M., de Oliveira, A. C. P., & Vieira, L. B. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.1972514 · Cited by 4
The impact of Type 2 diabetes in Parkinson’s diseasePreprint
Athauda, D. S., Evans, J., Wernick, A. I., Virdi, G. S., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2021) · medRxiv · doi:10.1101/2021.10.21.21265308 · Cited by 3
Long Covid and Neurodegenerative DiseasePreprint
Chambers, P. W. (2023) · Preprints.org · doi:10.20944/preprints202302.0027.v2 · Cited by 2
Žagare, A., Kurlovičs, J., Serra-Almeida, C., Ferrante, D., Frangenberg, D., Neises, L., Vitali, A., Gomez‐Giro, G., Jäger, C., Antony, P. M. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.03.592331 · Cited by 3
Avisar, H., Greenbaum, U., Djaldetti, R., & Lerner, B. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01003-1 · Cited by 3
The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson’s disease
Almohmadi, N. H., Al‐kuraishy, H. M., Hussein, K. S., Turkistani, A., Yousef, F. M., Al-Gareeb, A. I., Abdelaziz, A. M., Elewa, Y. H. A., & Batiha, G. E. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11014-w · Cited by 2
Istradefylline/ L‐DOPA Parkinson's disease therapy and energy coupling
Kanzato, N., Nakachi, K., & Mochizuki, S. (2024) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12820 · Cited by 2
We are what we eat — editors’ note on the role of diet in Parkinson's disease
Marras, C., & Obeso, J. A. (2019) · Movement Disorders · doi:10.1002/mds.27613 · Cited by 2
Lai, S. (2019) · Neurology · doi:10.1212/wnl.0000000000007458 · Cited by 2
Volpato, V., Menassa, D. A., Sheshadri, P., Giussani, S., Rokicki, M., Cardo, L. F., Bafaloukou, M., Schalkamp, A.-K., Zaremba, A., Monzón‐Sandoval, J., et al. (2025) · medRxiv · doi:10.1101/2025.05.28.25328401 · Cited by 2
Gut–Brain Axis: Role of Gut Microbiota in Neurodegenerative Disease
Narang, A., & Sandhir, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-6760-2_1 · Cited by 1
Role of PON1 L55M Gene Polymorphism in Parkinson’s Disease among North Indian Population
Kumar, B., Saluja, A., Juneja, A., Anand, K. S., Saraswathy, K. N., Longkumer, I., & Dhamija, R. K. (2024) · Neurology India · doi:10.4103/neuroindia.ni_596_20 · Cited by 1
Effect of methylglyoxal on Parkinson’s disease pathophysiology in the rotenone model
Çulpan, Y., Ozden, L., Gözderesi, Y., Koçak, B., Baltaci, Z. H., Denizli, A., Yılmaz, B., & Aker, R. G. (2024) · Marmara medical journal · doi:10.5472/marumj.1480086 · Cited by 1
Therapies Using Anti-diabetics to Prevent and Manage Progression of Parkinson's Disease
Rout, M., Prusty, S. K., & Kar, D. M. (2024) · Current Drug Therapy · doi:10.2174/0115748855332557240820054810 · Cited by 1
Zhang, H., Li, W., Wang, J., Wu, Z., Zhao, N., & Jiang, Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05063-5 · Cited by 1
GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70459 · Cited by 1
Amylin at the crossroads of type 2 diabetes and neurodegenerative diseases
Castillo, I. L. D., Garcia-Martin, J., Gutiérrez, A., & Moreno‐González, I. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103226 · Cited by 1
The Relation Between Type 2 Diabetes Mellitus and Parkinson Disease Up to Date
Rasanu, I. (2019) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2019-0009 · Cited by 1
Yeom, S., Yang, Y., & Kang, J. H. (2021) · Korean Journal of Adult Nursing · doi:10.7475/kjan.2021.33.5.448 · Cited by 1
Metadata
- Authors
- De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T.
- Affiliations
- From the Reta Lila Weston Institute of Neurological Studies, Department of Molecular Neurosciences (E.D.P.-F., A.J.N., T.T.W.), and Queen Square Brain Bank for Neurological Disorders (E.D.P.-F., T.T.W.), UCL Institute of Neurology, London; Unit of Health-Care Epidemiology (R.G., J.P.), Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford; and Preventive Neurology Unit (A.J.N.), Wolfson Institute of Preventive...
- Queen Mary University of London (GB)
- Venue
- Neurology
- Published
- 2018-07-10
- Volume
- 91
- Issue
- 2
- Pages
- e139-e142
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2807806732
- Cited by
- 242
- References
- 9
- Citations by year
- 2026: 23 · 2025: 21 · 2024: 36 · 2023: 28 · 2022: 29 · 2021: 35 · 2020: 34 · 2019: 26 · 2018: 9
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Prothena
- Barts Charity (MGU0364)
- National Institute for Health and Care Research (RNC/035/02)
- Parkinson's UK
- Brain Research Trust
- University College London
- University of Oxford
- Britannia Pharmaceuticals
- Medical Research Council (MR/L023784/2, MR/L023784/1)
- NIHR Oxford Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- type 2 diabetes, Parkinson's disease, risk factors, complicated diabetes, young adults, pathogenic pathways
- MeSH terms
- Adult, Age Factors, Aged, Diabetes Mellitus, Type 2, England, Female, Humans, Male, Middle Aged, Parkinson Disease, Retrospective Studies, Risk Factors, Comorbidity, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review